Compare Teck Resources (TECK) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teck Resources vs Travere Therapeutics Inc. Common Stock — how do they compare? Teck Resources trades at $63.23 (market cap $32.79B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Teck Resources is far larger — about 6.7× Travere Therapeutics Inc. Common Stock's market cap, and Teck Resources pays a 0.53% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teck Resources for 15 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TECK | TVTX | |
|---|---|---|
Market Cap | $32.79B | $4.88B |
Volume | 1,600,168 | 1,668,577 |
Sector | Basic Materials | Health |
52-Week High | $71.97 | $67.52 |
52-Week Low | $38.23 | $26.79 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $35.41B | $5.01B |
Dividend Yield | 0.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TECK trades at $67.17, down 0.55% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue and net income are projected to grow significantly in 2026, supported by a 17.85% net margin. Analyst consensus is strongly bullish, with 69% buy ratings, amid positive news flow including inclusion in Forbes' top companies for women and copper price optimism.
Outlook remains positive given earnings momentum and copper demand tailwinds, but risks include commodity price volatility and execution of the Anglo American merger. Cash flow turned positive in 2026 forecasts, though 2025 saw a net outflow. The stock offers value with a P/E of 18.82 and EV/EBITDA of 7.77, but investors should monitor merger progress and global economic conditions.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Teck Resources
Teck Resources is a mining company focused on producing metals and minerals, including copper and zinc. Its operations supply materials used in infrastructure, manufacturing, and energy-related industries.
Read more on TECK →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
